Mohammad Alashqar Shares Novel Antithrombin-Targeting Therapy for Hemophilia A and B
Mohammad Alashqar, Postdoctoral Pharmacotherapy Research Fellow at The Ohio State University College of Pharmacy, shared on LinkedIn:
“Grateful to share that my review paper, ‘Fitusiran: A Novel Antithrombin-Targeting Therapy for Hemophilia A and B, With or Without Inhibitors,’ has been published online today (12/26)
Sincere thanks to everyone who supported me throughout this journey—especially Dr. Milap Nahata for his mentorship, guidance, and invaluable feedback. This work would not have been possible without such support.
Looking forward to continuing contributions to hemophilia and thrombosis research.
Title: Fitusiran: A Novel Antithrombin-Targeting Therapy for Hemophilia A and B, With or Without Inhibitors
Authors: Mohammad Alashqar, Milap Nahata
Read the article.”
Deepen your hematology knowledge with Hemostasis Today.
-
May 29, 2026, 17:23Rita Schwab: Current Clinical Management of Trauma without the Use of Allogenic Blood Products
-
May 29, 2026, 17:22Brian Schiro: Excited to Provide Guideline Based Care at the Aortic Center
-
May 29, 2026, 17:20Martin Widschwendter: How Molecular Detection Tests Could Transform Endometrial Cancer Care
-
May 29, 2026, 17:18Nina Lansbury: Supporting a Period Friendly World With Menstrual Health Research and Education
-
May 29, 2026, 17:16Ipsita Chatterjee: Red is Not Shame, Red is Power, Red is a Woman
-
May 29, 2026, 16:49Abdulrahman Nasiri: The Evolving Role of Romiplostim in SAA
-
May 29, 2026, 16:46Soumen Bhattacharya: UC-II and Immune Modulation in Osteoarthritis
-
May 29, 2026, 16:38Ana Pedrero Gil: Red Blood Cell Transfusion Practice in Spain – High Inappropriateness Despite Low Overall Use
-
May 29, 2026, 15:40Lena Volland: Expanding Holistic Care in Bleeding Disorders Through Pelvic Health Physical Therapy at WFH Congress